This report represents Chordoma Foundation's responses to Charting Impact, a joint project of BBB Wise Giving Alliance, GuideStar USA Inc, and Independent Sector. Charting Impact uses five simple yet powerful questions to encourage strategic thinking and help organizations share concise information about their plans and progress toward impact.

Chordoma Foundation
PO Box 2127, Durham, NC
27702
919-809-6779
www.chordoma.org

Mission:
The Chordoma Foundation proactively initiates, facilitates, and funds research to accelerate the development of effective treatments, and ultimately a cure, for chordoma, while improving the diagnosis, treatment, and quality of life for people affected by this deadly bone cancer.

The content of this Charting Impact Report is the sole product and responsibility of Chordoma Foundation. This report does not in any way represent an endorsement from Independent Sector, BBB Wise Giving Alliance, or GuideStar, nor does it represent fulfillment of the BBB Wise Giving Alliance’s Standards for Charity Accountability. For more information on Charting Impact, visit www.guidestar.org/chartingimpact
1. What are we aiming to accomplish?

The Chordoma Foundation's mission is to improve the lives of those affected by chordoma and lead the search for a cure. This includes a goal of testing 10 highly promising treatments for chordoma in clinical trials by 2020.

2. What are our strategies for making this happen?

To accelerate the search for a cure, we initiate and fund high-impact research, facilitate information exchange and collaboration among researchers, and provide scientific resources needed to study chordoma. To help patients get the best care possible, we offer Patient Navigation Services for one-on-one support, provide information about the latest treatment options, refer patients to experienced doctors, and match patients with trained peer support mentors.

3. What are our organization's capabilities for doing this?

Building on our progress to date, we will continue to focus on key initiatives in patient services, healthcare improvement, and research. We will continue to grow our team, and create yearly goals with the support of our Board of Directors.

4. How will we know if we're making progress?

We continue to make progress in our urgent search for better treatments that can stop chordoma from progressing, improve quality of life, and ultimately, cure the disease. Tangible progress is evident by the increasing interest from researchers in studying chordoma, new treatment options, and extending the life of those diagnosed with chordoma.

5. What have and haven't we accomplished so far?

Better treatments. Better medical care. A better experience for chordoma patients and their families. Through new and enhanced Patient Services, we are now offering those affected by chordoma a place to turn for comprehensive information, guidance, and support throughout their journey with the disease. With new Healthcare Improvement initiatives, we are helping to raise the standard of care doctors provide to chordoma patients. Eight years of strategic investments in Research are paying off with a wave of promising new treatments moving toward clinical trials. Our investments in laboratory research have identified more than 20 potential treatment approaches for chordoma. And we continue investing in research to find vulnerabilities in chordoma to open doors to new treatments.